Capricor Therapeutics (CAPR) Payables (2010 - 2026)

Capricor Therapeutics' Payables history runs 17 years deep, the most recent figure standing at $3.9 million for Q1 2026.

• On a quarterly basis, Payables fell 25.23% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 25.23% decrease from a year earlier, with the FY2025 full-year figure at $1.7 million, down 49.61% from the prior year.
• Payables grew to $3.9 million in Q1 2026 per CAPR's latest filing, from $1.7 million in the prior quarter.
• Across five years, Payables topped out at $6.8 million in Q3 2023 and bottomed at $1.7 million in Q4 2025.
• The 5-year median for Payables is $4.8 million (2022), against an average of $4.7 million.
• Across the five-year window, Payables soared 75.78% in 2023 and plunged 58.36% in 2025, its largest moves.
• Year by year, Payables stood at $4.8 million in 2022, then grew by 29.28% to $6.3 million in 2023, then sank by 47.46% to $3.3 million in 2024, then tumbled by 49.61% to $1.7 million in 2025, then jumped by 137.37% to $3.9 million in 2026.
• Per Business Quant, the three latest CAPR Payables figures stand at $3.9 million (Q1 2026), $1.7 million (Q4 2025), and $2.7 million (Q3 2025).